What's Happening?
The FDA's Oncologic Drugs Advisory Committee (ODAC) recently voted against AstraZeneca's oral selective estrogen receptor degrader (SERD) drug camizestrant for first-line treatment of HR-positive, HER2-negative breast cancer with ESR1 mutations. The panel
concluded that the SERENA-6 trial data did not support its use in combination with CDK inhibitors due to a lack of statistically significant overall survival benefit. However, the ODAC voted in favor of AstraZeneca's AKT inhibitor Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 study results. The FDA's decision on camizestrant is pending, with further data expected later this year.
Why It's Important?
The ODAC's decisions highlight the challenges pharmaceutical companies face in gaining approval for new cancer treatments. While camizestrant showed promise in reducing disease progression, the lack of overall survival benefit raises questions about its clinical value. On the other hand, the approval of Truqap for prostate cancer offers new hope for patients with limited treatment options. These outcomes underscore the importance of robust clinical trial data and the FDA's role in ensuring the safety and efficacy of new therapies.
What's Next?
AstraZeneca plans to present additional data from the SERENA-6 trial at the upcoming ASCO congress, which may influence the FDA's final decision on camizestrant. The company is also pursuing regulatory approval for camizestrant in other countries. Meanwhile, the approval of Truqap for prostate cancer could lead to increased testing for PTEN mutations and expanded treatment options for patients.
